Clinical trials: T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Haematological Malignancies
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)
The purpose of this study is to evaluate whether the administration of allodepleted donor T cells to patients with haematological malignancies after stem cell transplant can improve the recovery of the patients immune system.
- Trial name
- ICAT (NCT01827579)
- Testing
- CD25/71 allodepleted donor T-cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- University College, London
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma
- Trial name
- NCT00003269
- Testing
- sargramostim, amifostine trihydrate, cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Scripps Health
Leukemia
Biomarkers to Classify Young Patients With Acute Lymphoblastic Leukemia (ALL) and Remission Induction Therapy in Young Patients With B-Precursor ALL
RATIONALE: Studying samples of blood or bone marrow from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01225874
- Testing
- SC-PEG E. coli L-asparaginase, cytarabine, daunorubicin hydrochloride
- Volunteers
- 3,762 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
- Conditions
- Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT02742727
- Testing
- anti-CD7 CAR-pNK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
CAR19PK is a research study evaluating the use of lymphodepleting chemotherapy and chimeric antigen receptor (CAR) T cell therapy, a type of cellular therapy, for the treatment of refractory and/or relapsed leukemia.
- Trial name
- NCT06847269
- Testing
- Fludarabine, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant
RATIONALE: Vaccines made from the patient's cancer cells may help the body build an effective immune response to kill cancer cells.
- Trial name
- NCT00469820
- Testing
- autologous tumor cell vaccine, peripheral blood lymphocyte therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Immune System Diseases
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
The body has different ways of fighting infection and disease. No single way is effective at fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells.
- Conditions
- Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
- Trial name
- NCT03016377
- Testing
- iC9-CAR19 cells, Rimiducid, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)
MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia
This phase II trial is studying how well giving MS-275 together with GM-CSF works in treating patients with myelodysplastic syndrome and/or relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00462605
- Testing
- entinostat, sargramostim
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy, Acute Myeloid Leukemia
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
This is a unique dose-escalation trial that will titrate doses of umbilical cord blood (UCB) Treg and CD3+ Teff cells with the goal of infusing as many CD3+ Teff cells as possible without conferring grade II-IV acute…
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia in Blast Crisis
- Trial name
- NCT01163201
- Testing
- Treg cells, CD3+ Teff cells, Fludarabine
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies.
- Trial name
- NCT04264039
- Testing
- anti-CD19 UCAR-T cells, Fludarabine, Cytoxan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinqiao Hospital of Chongqing
Graft vs Host Disease, Myelodysplastic Syndromes
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donors T lymphocytes have undergone "selective depletion." Certain patients with cancers of the blood undergo transplantation of…
- Conditions
- Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Leukemia, Myeloid
- Trial name
- NCT00025662
- Testing
- RFT5-SMPT-dgA, Isolex system
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoma
Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00363090
- Testing
- alemtuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Toronto Sunnybrook Regional Cancer Centre
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Peripheral T-cell Lymphoma
- Trial name
- NCT01336920
- Testing
- carfilzomib
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Nebraska
Lymphoma, B-Cell, Acute Lymphoblastic Leukemia, Pediatric
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
This study seeks to examine the efficacy and safety of the administration of autologous T cells that have been modified through the introduction of a chimeric antigen receptor (CAR) targeting the B cell surface antigen CD19…
- Trial name
- NCT06866873
- Testing
- CAR-T
- Where
- Hong Kong
- Volunteers
- 18 people
- Sponsor
- Hong Kong Children's Hospital
Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult
Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL
In recent years, immunotherapy (eg. blinatumomab, inotuzumab ozogamicin, CAR-T cells) has demonstrated a high safety and efficacy profile in relapsed/refractory (R/R）B-ALL.
- Trial name
- NCT06481241
- Testing
- CAR-T cells, Venetoclax
- Where
- China
- Volunteers
- 77 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Precursor Cell Lymphoblastic Leukemia-Lymphoma
De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)
No high-dose methotrexate (MTX) and high-dose cytarabine (ARA-C) consolidation blocks, L-asparaginaseis scheduled for 1 year of treatment, 21 intrathecal injections through the whole treament, T-ALL patients in complete remossion…
- Trial name
- NCT03462095
- Testing
- Autologous HSCT
- Where
- Russia
- Volunteers
- 350 people
- Sponsor
- National Research Center for Hematology, Russia
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia
Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation.
- Conditions
- Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT04128501
- Testing
- Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
T-Cell Leukemia/Lymphoma, Adult
Novel Therapeutic Approach for Human T-cell Malignancies
This multicenter translational study, with prospective and retrospective samples, aims to identify new strategies to selectively eliminate neoplastic T cells by modulating intracellular ROS levels.
- Trial name
- NCT06600568
- Testing
- Translation analysis
- Where
- 2 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.